Chipscreen(688321)2024-08-29 09:11Group 1: Company Performance - In the first half of 2024, the company achieved revenue of approximately 302 million CNY, a year-on-year increase of 25.06% [2] - Sales of the drug Sidabamine increased by 11.74%, with revenue growth of 4.15% [2] - Sales of the drug Siglitazone saw a remarkable increase of 396.15%, with revenue growth of 632.48% [2] Group 2: Research and Development Progress - The company has made significant progress in R&D, with 2上市申请 (上市申请) and 2临床申请 (clinical applications) approved, and 2 clinical trials completed [2] - Multiple R&D projects are underway across five major therapeutic areas, focusing on candidates with Best in Class potential [2] Group 3: Clinical Trials and Drug Development - The III phase trial for the drug Westoroni targeting small cell lung cancer has concluded, with NDA submission timing dependent on Pre-NDA communication [3] - The II phase clinical trial for Siglitazone in treating Non-Alcoholic Steatohepatitis (NASH) has shown promising results, with data to be presented at the American Liver Meeting in October-November 2024 [4] Group 4: Market Strategy and Investor Relations - The company plans to participate in the national medical insurance negotiations for Siglitazone and Sidabamine, with pricing subject to negotiation outcomes [4] - The company has decided not to lower the conversion price of its convertible bonds, maintaining investor interests [4]